VRTX241115C480000
- 22.80
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$7.83 Million in Common Stock
Chevron, Super Micro Computer Top List of Most Shorted Large-cap Stocks in October, Hazeltree Says
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock
Market Opens to Fresh Highs | Live Stock
Investors Elect to Accelerate Market on Election Week | Weekly Buzz
Friday Market Finished with Records | Wall Street Today
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 7.83 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 8, $Vertex Pharmaceuticals(VRTX.US)$ Officer Kewalramani Reshma intends to sell 15,198 shares of its common stock on Nov 8, with a total market value of approximately $7.83
TSLA Up, China Down, Friday Market Quiet After Loud, Decisive Week | Live Stock
FOMC Cut Sends Prices Up, Election Blitz Strong | Wall Street Today
Market Hits All-Time Highs on FOMC Rate Day | Live Stock
Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
Market Prices in Trump Victory with Index Records | Wall Street Today
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Market Trumps Past Records Wednesday Afternoon | Live Stock
Vertex Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $408
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $486 to $600
Vertex Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Vertex Pharmaceuticals: Strong Financial Performance and Innovative Drug Pipeline Underpin Buy Rating